Results from real patients
Semaglutide research you can use
See what changed in people's weight, blood sugar, hearts, kidneys, and daily comfort.
What Semaglutide changes after a meal
Semaglutide started out as a stand-in for a message your gut sends. Researchers wanted that message to last instead of fading.
Doctors call the gut message GLP-1. Your body sends it out after you eat.
GLP-1 tells your pancreas when to put out insulin. Insulin's the hormone that lets sugar leave your bloodstream and feed your cells.
It also turns down glucagon, a hormone that pushes your blood sugar up. You're helped from both sides.
Your stomach holds a meal longer. Your brain gets a stronger “that's enough” signal too.
Your own GLP-1 is gone in minutes. Semaglutide sticks around about a week.
Large studies then tested it. People lost weight and their blood sugar improved.
High-risk groups had less heart and kidney trouble. Those gains don't cancel the warnings.
A 2025 study put Semaglutide against tirzepatide. Tirzepatide took off more weight.
When people quit it, much of their weight returned. So it only helps while you're taking it.
What Semaglutide is made of, and who can prescribe it
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a medicine that switches on the same receptor as the natural gut hormone GLP-1. Structurally it is a 31-amino-acid analogue of human GLP-1 with about 94% of the same sequence. Two deliberate changes make it last: a substitution at position 8 (alpha-aminoisobutyric acid in place of alanine) blocks the enzyme DPP-4 that normally chews up GLP-1 within minutes, and a fatty-acid chain attached to the peptide binds tightly but reversibly to albumin, the most abundant protein in blood, which shields the drug from being filtered out by the kidneys. Together these give an elimination half-life of about one week. It is supplied as a once-weekly subcutaneous injection and as a once-daily oral tablet.
For clinical access, the gate is an individual review: a licensed Promise Peptides clinician (mypromise.com) may prescribe Semaglutide only after deciding it is appropriate for that patient.
How Semaglutide changes hunger and blood sugar
Semaglutide copies the gut hormone GLP-1. It acts in your gut, your brain and your pancreas.
As your sugar rises after a meal, your pancreas puts out more insulin. It holds back glucagon, the sugar-raising hormone, too.
Since it mostly works while your sugar's high, it rarely drives your sugar too low on its own. Meals also linger in your stomach.
Most of the weight change comes from the brain. Hunger drops, but your body doesn't burn calories faster.
One study tracked that in rats and mice [4]. It wasn't done in people.
The drug got into the brain's appetite centers. The animals cut back on food and chose different things to eat.
Their bodies weren't burning extra energy. The change came from turned-down hunger.
For you, that may mean feeling full sooner. Thoughts about food may quiet down too.
Animal results can't promise the same in you. Weight studies in people are a firmer guide.
What Semaglutide changed about body weight
STEP 1 gave the plainest weight result. The adults in it were heavy or had obesity.
None of them had diabetes. Each got a shot under the skin once a week.
At the week 68 check, the Semaglutide group's average loss was 14.9% of body weight [1]. The placebo group lost 2.4%.
A placebo is a dummy shot with no medicine. It shows what the drug itself changed.
Blood pressure and waist size improved too. So did cholesterol and other fats in the blood, sugar, and the tests for inflammation, the body's swelling response [11].
Those gains held while people stayed on it. Much of the benefit faded after they stopped.
After STEP 1, researchers followed people for another year off the drug. A big part of the lost weight returned [15].
Heart and blood-sugar gains slid back as well. Semaglutide isn't a one-time cure.
What Semaglutide did for hearts and kidneys
SUSTAIN-6 was a heart study in high-risk adults. All of them had type 2 diabetes.
Heart attacks, strokes and heart deaths came less often on Semaglutide. The researchers were 95% sure that wasn't luck [2].
Eye trouble rose in some people. They already had eye damage from diabetes.
Their blood sugar had also fallen fast. Their eye problems came about 1.76 times as often, and again researchers were 95% sure of the gap.
A second heart study took in 17,604 adults. All of them carried obesity and heart disease, yet none had diabetes.
Heart attacks, strokes and heart deaths fell by 20%. That result, too, was 95% sure to be more than chance [3].
The kidney study took in 3,533 people. Each had kidney disease and type 2 diabetes.
Serious kidney events fell by 24%, and researchers were 95% sure of it [6]. A serious event meant the kidneys failed, or the person died of kidney or heart disease.
It also counted if kidney cleaning fell by half or more. Doctors measure that cleaning of the blood with a routine blood test.
These are group results; they don't promise you anything. Your own health changes the odds.
Another study checked four common medicines taken alongside it [12]. Semaglutide didn't move how much of each drug was in the blood by an amount that'd matter.
They were metformin, a diabetes pill; warfarin, a blood thinner; atorvastatin, a cholesterol pill; and digoxin, a heart pill. A serious clash didn't look likely.
How Semaglutide and tirzepatide changed weight
The 2025 study was called SURMOUNT-5. It took in 751 adults with obesity.
Tirzepatide acts like two of your gut's hormones at once. Their medical names are GIP and GLP-1.
Semaglutide copies GLP-1 alone. At 72 weeks, people on tirzepatide had lost 20.2% of their weight on average, against 13.7% on Semaglutide.
Chance couldn't easily explain a gap that size [7]. Tirzepatide won on this one measure; that's all it settled.
One weight result can't settle everything for you. The study didn't answer comfort, cost or access.
It also didn't replace the long heart and kidney studies. Semaglutide has more years of those.
Take the whole record to your doctor. Your own health and comfort still count most.
What Semaglutide changed in blood-sugar studies
SUSTAIN 7 put two weekly GLP-1 shots side by side in type 2 diabetes. One shot was Semaglutide.
The other was dulaglutide, another weekly diabetes drug. Semaglutide took off more weight, and it lowered more the blood test for your average sugar across three months [9].
A separate pill study took in people with type 2 diabetes. Their earlier treatment hadn't kept their blood sugar in check.
It compared 25 mg and 50 mg pills with 14 mg. The larger amounts improved both weight and blood sugar [10].
They're study amounts, not your treatment plan. They show you where Semaglutide stands next to similar drugs.